| Predicate |
Object |
| assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_af41892422640152790731dcabd414ae |
| classificationCPCAdditional |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K2121-00 |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-0019
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/B65B55-08
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-439
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-16
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-485
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-08
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P25-36
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K47-10
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P25-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K47-02
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P25-04
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-10
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K47-26
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/B65B55-16
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/B65B3-003
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-1682 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P25-36
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K47-10
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P25-04
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K47-02
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K9-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K9-10
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-485 |
| filingDate |
2010-06-08-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_ed316ba3cf94c56251e69dffdce9c0b5
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_26f65cddb97aa0abd43dd36b073b24c7 |
| publicationDate |
2014-10-15-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
GB-2513060-A |
| titleOfInvention |
Microparticle buprenorphine suspension |
| abstract |
A composition comprises a suspension of 5-20wt% of buprenorphine in water; and polyethylene glycol (PEG) polymer, wherein the buprenorphine is in particulate form with an average particle size of less than 200µm for the treatment of opioid dependence or pain relief comprising administering the composition parenterally and extravascularly. Preferably the average particle size of buprenorphine is less than 20µ and may be present as the free base (unprotonated) or as the protonated salt. The PEG preferably has a molecular weight of 1000 to 10,000. The composition may further comprise a non-ionic surfactant such as polysorbate 80, polysorbate 20, poloxamers and phospholipids; pharmaceutically acceptable salts or sugars to adjust the tonicity of the composition; and/or preservatives selected from the group including methylparaben, propylparaben and benzyl alcohol. The composition preferably delivers a therapeutically effective dosage of the buprenorphine in an amount of 0.1 to 10mg per day. |
| priorityDate |
2010-06-08-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |